Boehringer Ingelheim inks USD500M immunology deal with Sitryx to target autoimmune disease

UK—Boehringer Ingelheim has strengthened its immunology pipeline through a licensing agreement with Sitryx Therapeutics valued at over USD500 million (£395 million).

The deal centers on Sitryx’s early-stage immunometabolic program, which features several oral small molecule inhibitor candidates targeting an undisclosed novel mechanism.

Boehringer has described these candidates as potentially disease-modifying options for specific inflammatory and autoimmune conditions.

Under the agreement, Boehringer gains exclusive global rights to Sitryx’s preclinical program.

The German pharmaceutical giant will provide undisclosed upfront and near-term payments to the British biotech company.

Sitryx stands to receive development, regulatory, and commercialization milestone payments exceeding USD 500 million, alongside tiered royalties on future sales if any drug from the partnership reaches the market.

Carine Boustany, head of immunology and respiratory diseases research at Boehringer Ingelheim, emphasized the urgent need for innovation in autoimmune and inflammatory diseases.

She noted that Sitryx’s small molecule inhibitor program introduces a promising new mechanism that aligns with the company’s focus on advancing first-in-class approaches.

According to GlobalData’s Pharmaceutical Intelligence Center, Boehringer Ingelheim signed more licensing deals in 2025 than in any year over the past decade.

More than half of these agreements focused on oncology and immunology.

FDA grants frontline approval for Hernexeos

Separately, Boehringer has expanded its oncology portfolio through US accelerated approval of Hernexeos (zongertinib), a tyrosine kinase inhibitor, for frontline treatment of HER2-mutant non-small cell lung cancer.

This marks the second therapy to receive FDA clearance through the Commissioner’s National Priority Voucher pilot program, which has sparked debate among experts regarding voucher award prioritization.

Boehringer previously secured FDA approval for Hernexeos in chemotherapy-refractory NSCLC in August 2025.

The frontline approval stems from results of the Phase Ib Beamion LUNG-1 trial, where the drug achieved an objective response rate of 76% in treatment-naïve patients.

To obtain full approval, Boehringer is enrolling patients in the confirmatory Beamion LUNG-2 study, which is expected to reach primary completion in November 2026.

Shifting treatment landscape

Hernexeos now stands as the only targeted therapy approved for treatment-naïve patients with HER2-mutant NSCLC.

However, Bayer is pursuing a similar indication for its recently approved tyrosine kinase inhibitor, Hynruo (sevabertinib), through the Phase III SOHO-02 study.

Currently, the standard of care for HER2-mutant NSCLC involves chemotherapy with or without immunotherapy.

Shashank Deshpande, board chair and head of human pharma at Boehringer Ingelheim, stated that Hernexeos’ approval will mark a shift towards personalized care for patients with this type of lung cancer.

A 2024 paper published in Clinical Lung Cancer estimates that between 1% and 7% of NSCLC patients have HER2-mutated disease.

Practicing oncologist and NSCLC expert Balazs Halmos told Clinical Trials Arena that physicians will find it challenging to prioritize either Bayer’s sevabertinib or Hernexeos based on efficacy and safety alone.